Tsuyoshi Mikkaichi
Overview
Explore the profile of Tsuyoshi Mikkaichi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyano T, Hirouchi M, Yoshimura N, Hattori K, Mikkaichi T, Kiyosawa N
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769285
Schizophrenia is a complex and heterogenous psychiatric disorder characterized by positive, negative, and cognitive symptoms. Our previous study identified three subgroups of schizophrenia patients based on plasma microRNA (miRNA) profiles....
2.
Miyano T, Mikkaichi T, Nakamura K, Yoshigae Y, Abernathy K, Ogura Y, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673876
Schizophrenia is a complex and heterogenous psychiatric disorder. This study aimed to demonstrate the potential of circulating microRNAs (miRNAs) as a clinical biomarker to stratify schizophrenia patients and to enhance...
3.
Yamamura N, Mikkaichi T, Itokawa K, Hoshi M, Damme K, Geigner S, et al.
Xenobiotica
. 2022 Sep;
52(9-11):997-1009.
PMID: 36170033
Mirogabalin is a αδ ligand as well as pregabalin. The aim of this study was to clarify whether mirogabalin is a substrate of human LAT1, which involved in absorption and...
4.
Kato T, Mikkaichi T, Yoshigae Y, Okudaira N, Shimizu T, Izumi T, et al.
Int J Pharm
. 2021 Feb;
597:120349.
PMID: 33545293
The purpose of this study was to evaluate the impact of P-glycoprotein (P-gp) efflux on edoxaban absorption in gastrointestinal tracts quantitatively by a physiologically based pharmacokinetic (PBPK) model constructed with...
5.
Kato T, Nakagawa H, Mikkaichi T, Miyano T, Matsumoto Y, Ando S
Eur J Pharm Biopharm
. 2020 Apr;
151:45-52.
PMID: 32298756
This paper presented how to establish a clinically relevant specification (CRS) using in silico physiologically based pharmacokinetic (PBPK) modeling. Three different formulations of model drug products were used in the...
6.
Fukui S, Yano H, Yada S, Mikkaichi T, Minami H
Asian J Pharm Sci
. 2020 Feb;
12(2):149-156.
PMID: 32104324
The purpose of this study was to develop an extended-release (ER) matrix tablet that shows robust dissolution properties able to account for the variability of pH and mechanical stress in...
7.
Mikkaichi T, Yeaman M, Hoffmann A
PLoS Comput Biol
. 2019 Jul;
15(7):e1007087.
PMID: 31295255
Persistent bacteremia caused by Staphylococcus aureus (SA), especially methicillin-resistant SA (MRSA), is a significant cause of morbidity and mortality. Despite susceptibility phenotypes in vitro, persistent MRSA strains fail to clear...
8.
Mikkaichi T, Nakai D, Yoshigae Y, Imaoka T, Okudaira N, Izumi T
Drug Metab Pharmacokinet
. 2015 Sep;
30(5):334-40.
PMID: 26403085
Organic anion transporting polypeptide (OATP) 1B1 and 1B3 are key molecules that are involved in hepatic uptake related to drug elimination, and OATP-mediated drug interactions are of clinical concern. In...
9.
Karibe T, Hagihara-Nakagomi R, Abe K, Imaoka T, Mikkaichi T, Yasuda S, et al.
Pharm Res
. 2014 Nov;
32(5):1634-47.
PMID: 25380981
Purpose: To evaluate whether the impact of functional modulation of the breast cancer resistance protein (BCRP, ABCG2 421C>A) on human pharmacokinetics after oral administration is predictable using Bcrp knockout mice...
10.
Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al.
Drug Metab Dispos
. 2014 Jan;
42(4):520-8.
PMID: 24459178
Edoxaban (the free base of DU-176b), an oral direct factor Xa inhibitor, is mainly excreted unchanged into urine and feces. Because active membrane transport processes such as active renal secretion,...